BostonGene Wins Three Gold Stevie® Awards

Company of the Year, New Product of the Year, and Technology Breakthrough of the Year honors recognize AI that simulates how a patient’s tumor and immune system will respond to therapy before clinical testing

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, developer of an AI model for tumor and immune biology, today announced that it has been awarded three Gold Stevie^® Awards in the 2026 Stevie^® Awards for Technology Excellence, taking top honors as Company of the Year, New Product of the Year, and Technology Breakthrough of the Year in Biotechnology.

The awards recognize a fundamental shift in how oncology drugs are developed. Traditional AI approaches in drug development often rely on retrospective analysis to predict clinical outcomes. BostonGene goes beyond prediction with biologically grounded Simulational AI, modeling how therapeutic interventions may affect tumor and immune biology. By translating multimodal patient data into disease-level simulations and actionable biological insights, the platform helps biopharmaceutical partners prioritize development programs, identify responsive patient populations, and design more precise clinical trials.

BostonGene received top honors in the following categories:

• Company of the Year – Biotechnology
  BostonGene was honored for uniting biologically grounded AI, proprietary multimodal patient data, and clinical-grade laboratory capabilities into a single decision platform for drug development. In collaborations with global biopharmaceutical companies, BostonGene has prioritized indications with the strongest biological rationale and identified a biomarker-selected patient population with a nearly threefold higher response rate.

• New Product of the Year – Biotechnology:
  BostonGene’s Foundation Model for Drug Effect Prediction was recognized for advancing drug development beyond retrospective prediction toward prospective, biology-driven evaluation of therapeutic effects. Built on a proprietary diffusion-based architecture, the model creates patient-specific digital representations of tumor and immune biology and simulates how a therapy will act across molecular, cellular, and tissue levels. By linking a drug’s mechanism of action to both efficacy and immune-mediated safety risk before clinical testing, it gives development teams critical evidence at the point when decisions cost the least to change.

• Technology Breakthrough of the Year – Biotechnology
  BostonGene’s Multimodal AI for Trial Design Optimization was recognized for transforming how partners design clinical trials. The platform integrates tumor, immune, and clinical data to guide patient selection, biomarker strategy, and adaptive trial design at every stage of development. It turns complex and incomplete datasets into clear development decisions, helping partners reduce risk and focus resources on the patients most likely to benefit.

“Most AI in drug development learns from what has already happened,” said Andrew Feinberg, President and CEO of BostonGene. “We built our AI models to simulate what will happen, grounded in how a patient’s tumor and immune system actually behave. That lets our partners see a therapy’s likely effect before the first patient is enrolled. These awards recognize that shift. Our focus is helping partners reduce development risk, make confident pipeline decisions, and bring the right therapies to the patients who need them.”

BostonGene’s proprietary platform is anchored by a CLIA-certified, CAP-accredited laboratory and supported by extensive clinical validation. Its underlying methodologies and clinical reliability are backed by peer-reviewed publications in top-tier journals, including Cancer Cell, Cancer Discovery, Nature, Cell Reports Medicine, Frontiers in Oncology, and Modern Pathology, as well as research presentations at major scientific congresses such as AACR, ASCO, ASH, ESMO, SITC, SABCS, and JSMO.

About BostonGene Corporation
BostonGene powers an AI model of tumor and immune biology to deliver disease-level insights and enable precision decision-making across oncology and immune-mediated diseases, spanning drug development and clinical care. By integrating multimodal data, including genomic, transcriptomic, immune, and clinical signals, BostonGene generates biologically grounded intelligence to optimize patient selection, trial design, and therapeutic strategy. This creates a scalable AI decision layer that improves development outcomes and clinical management. BostonGene partners with leading biopharmaceutical organizations and academic institutions to accelerate the delivery of precision therapies while continuously expanding its capabilities across new diseases and complex biological systems. For more information, visit www.BostonGene.com.